The stock has more than 15.6 million shares traded and over 24,963 trades in pre-market. Shares are trending at .51
(24/7 MARKET NEWS) Akebia Therapeutics (Nasdaq: AKBA) announced, after yesterday’s market close, that it’s regaining rights to Vadadustat in the in the United States, Europe, China, Russia, Canada, Australia, the Middle East, and certain other territories. Additionally, the biopharmaceutical company will receive a $55M settlement fee.
Akebia Therapeutics is trading at $0.48, up $0.13 (+36.79%), on 7,691,049 shares. Wednesday’s session was the first time in over two months that it traded above 50 cents, only to drift back down to close yesterday at $0.3531. If it can break through the 55 cent level on high volume, it should have low resistance to the 75 cent level and then it should begin to refill a large gap into the $1,50 range.[mstock id=”73007″ asset=”akba”]
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium…
- Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
- Akebia to assume responsibility for regulatory review processes previously led by Otsuka
CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka). As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.